Results 41 to 50 of about 23,495,426 (286)

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study [PDF]

, 2015
Objectives The interleukin-6 receptor (IL-6R) blocker tocilizumab (TCZ) reduces inflammatory disease activity in rheumatoid arthritis (RA) but elevates lipid concentrations in some patients.
Bathon, Joan M., Beaulieu, Andre D., Carlson, Timothy H., Codding, Christine E., Delles, Christian, Giles, Jon T., Lee, Janet S., McInnes, Iain B., Salmon, Jane E., Sattar, Naveed, Thompson, Liz   +10 more
core   +1 more source

Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes

American Journal of Preventive Cardiology, 2023
Objective: Elevated lipoprotein(a) [Lp(a)] is associated with atherosclerotic cardiovascular disease, yet little is known about Lp(a) testing patterns in real-world practice.
Michelle D. Kelsey, Hillary Mulder, Karen Chiswell, Zachary M. Lampron, Ester Nilles, Jacquelyn P. Kulinski, Parag H. Joshi, W. Schuyler Jones, Alanna M. Chamberlain, Thorsten M. Leucker, Wenke Hwang, M. Wesley Milks, Anuradha Paranjape, Jihad S. Obeid, MacRae F. Linton, Shia T. Kent, Eric D. Peterson, Emily C. O'Brien, Neha J. Pagidipati   +18 more
doaj   +1 more source

Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children. [PDF]

, 2016
BackgroundGlycosylation patterns of serum proteins, such as α1-acid glycoprotein, are modified during an acute phase reaction. The response of acute Kawasaki disease (KD) patients to IVIG treatment has been linked to sialic acid levels on native IgG ...
Burns, Jane C, Connelly, Margery A, Kanegaye, John T, Otvos, James D, Pourfarzib, Ray, Shalaurova, Irina, Shimizu, Chisato, Tremoulet, Adriana H, Winegar, Deborah A   +8 more
core   +3 more sources

Lipoprotein apheresis to treat elevated lipoprotein (a) [PDF]

Journal of Lipid Research, 2016
An elevated plasma concentration of lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease. Life style modification and currently available drugs either fail to effectively lower plasma Lp(a) levels or do not result in clinical benefit. However, lipoprotein apheresis is very efficient in decreasing Lp(a) concentrations.
Elisa Waldmann, Klaus G. Parhofer
openaire   +2 more sources

A saposin-lipoprotein nanoparticle system for membrane proteins. [PDF]

, 2016
A limiting factor in membrane protein research is the ability to solubilize and stabilize such proteins. Detergents are used most often for solubilizing membrane proteins, but they are associated with protein instability and poor compatibility with ...
Armache, Jean-Paul, Briggs, John AG, Cheng, Yifan, Flayhan, Ali, Frauenfeld, Jens, Garoff, Henrik, Guettou, Fatma, Jegerschöld, Caroline, Löving, Robin, Löw, Christian, Moberg, Per, Nordlund, Pär, Sonnen, Andreas F-P, Zhu, Lin   +13 more
core   +2 more sources

Lipoprotein(a) as a cardiovascular risk factor: current status

European Heart Journal, 2010
Aims The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp(a), on desirable levels, and on therapeutic strategies.
B. Nordestgaard, M. Chapman, K. Ray, J. Borén, F. Andreotti, G. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. Descamps, E. Fisher, P. Kovanen, J. Kuivenhoven, P. Lesnik, L. Masana, Ž. Reiner, M. Taskinen, L. Tokgözoğlu, A. Tybjærg-Hansen   +18 more
semanticscholar   +1 more source

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)‐Free Low‐Density Lipoprotein Cholesterol

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Accurate measurement of the cholesterol within lipoprotein(a) (Lp[a]‐C) and its contribution to low‐density lipoprotein cholesterol (LDL‐C) has important implications for risk assessment, diagnosis, and treatment of atherosclerotic ...
Weili Zheng, Michael Chilazi, Jihwan Park, Vasanth Sathiyakumar, Leslie J. Donato, Jeffrey W. Meeusen, Mariana Lazo, Eliseo Guallar, Krishnaji R. Kulkarni, Allan S. Jaffe, Raul D. Santos, Peter P. Toth, Steven R. Jones, Seth S. Martin   +13 more
doaj   +1 more source

Effects of Diet Composition and Insulin Resistance Status on Plasma Lipid Levels in a Weight Loss Intervention in Women. [PDF]

, 2016
BackgroundOptimal macronutrient distribution of weight loss diets has not been established. The distribution of energy from carbohydrate and fat has been observed to promote differential plasma lipid responses in previous weight loss studies, and insulin
Flatt, Shirley W, Heath, Dennis D, Le, Tran, Natarajan, Loki, Pakiz, Bilge, Quintana, Elizabeth L, Rana, Brinda K, Rock, Cheryl L   +7 more
core   +3 more sources

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9 [PDF]

, 2017
BACKGROUND: A beneficial effect on cardiovascular risk may be obtained by improving lipid-related serum lipoprotein functions such as high-density lipoproteins (HDLs) cholesterol efflux capacity (CEC) and serum cholesterol loading capacity (CLC) and by ...
Adorni, Maria Pia, Bernini, Franco, Ferri, Nicola, Izzo, Raffaele, Marchiano, Silvia, Rozza, Francesco, Trimarco, Valentina, Zimetti, Francesca   +7 more
core   +3 more sources

The Carboxyl-Terminal Segment of Apolipoprotein A-V Undergoes a Lipid-Induced Conformational Change [PDF]

, 2010
Apolipoprotein (apo) A-V is a 343-residue, multidomain protein that plays an important role in regulation of plasma triglyceride homeostasis. Primary sequence analysis revealed a unique tetraproline sequence (Pro293-Pro296) near the carboxyl terminus of ...
Lee, B. L., Mauldin, Kasuen, Oleszczuk, M., Ryan, R. O., Sykes, B. D.   +4 more
core   +2 more sources